Trial reportHeart (British Cardiac Society)2005
Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure.
Trial report in Heart (British Cardiac Society), 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Coenzyme QFrontiers in cardiovascular medicine · 2022Pooled it
- Effect of Uric Acid-Lowering Agents on Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.Frontiers in cardiovascular medicine · 2021Pooled it
- Efficacy and safety of the urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia: results from the LEAF-CHF study.Heart and vessels · 2025Trial
- Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.European journal of heart failure · 2022Trial
- Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial.The Journal of international medical research · 2021Trial
- A Randomized Controlled Trial of Allopurinol in Patients With Peripheral Arterial Disease.The Canadian journal of cardiology · 2016Trial
- Trial
- Trial
- Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial.Lancet (London, England) · 2010Trial
- The effect of allopurinol on the cerebral vasculature of patients with subcortical stroke; a randomized trial.British journal of clinical pharmacology · 2009Trial
- Update in uric acid, hypertension, and cardiovascular diseases.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Review
- Notopterol Ameliorates Hyperuricemia-Induced Cardiac Dysfunction in Mice.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Clinical Implications of Uric Acid in Heart Failure: A Comprehensive Review.Life (Basel, Switzerland) · 2021Review
- Xanthine Oxidoreductase Inhibitors.Handbook of experimental pharmacology · 2021Article
- Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure.Heart failure reviews · 2020Review
- The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor.Oxidative medicine and cellular longevity · 2020Review
- Is Hyperuricemia, an Early-Onset Metabolic Disorder, Causally Associated with Cardiovascular Disease Events in Han Chinese?Journal of clinical medicine · 2019Article
- Hyperuricemia treatment in acute heart failure patients does not improve their long-term prognosis: A propensity score matched analysis from the AHEAD registry.Clinical cardiology · 2019Article
- Treating oxidative stress in heart failure: past, present and future.European journal of heart failure · 2019Review
- Shortage of Cellular ATP as a Cause of Diseases and Strategies to Enhance ATP.Frontiers in pharmacology · 2019Article
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo study whether the effect of allopurinol on improvement of endothelial dysfunction in chronic heart failure (CHF) translates into improved exercise capacity and to examine whether allopurinol also improves B-type natriuretic peptide (BNP), the other important prognostic marker of CHF.
designRandomised, double blind, placebo controlled crossover trial.
settingTeaching hospital. PATIENTS: 50 patients with CHF (New York Heart Association functional classes II and III) were recruited.
interventions50 patients with CHF were randomly assigned to three months' treatment with allopurinol (300 mg/day) or placebo. At two and three months into treatment, they underwent a modified Bruce exercise protocol and a six minute walk test. Blood was taken for BNP and haemoglobin analysis.
resultsNeither exercise test was altered by allopurinol. However, plasma BNP concentrations fell significantly (p = 0.035) with allopurinol (11.9 pmol/l) versus placebo (14.4 pmol/l). Haemoglobin concentrations also fell highly significantly with allopurinol (p = 0.001).
conclusionsAn important negative finding is that despite high hopes for it, allopurinol had no effect on exercise capacity in CHF. On the other hand, allopurinol did reduce BNP, which is the best available surrogate marker for prognosis in CHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.